Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Glenmark Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here
Glenmark, Particle Sciences ink deal to develop generic cancer drug Abraxane
As per the terms of the agreement, Glenmark has obtained exclusive global marketing and distribution rights to the product upon commercialization Glenmark announces Strategic Development and Global Licensing Agreement with Particle Sciences, Inc., a Lubrizol Company, for generic ABRAXANE
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 19, 2016, titled "Glenmark announces Strategic Development and Global Licensing Agreement with Particle Sciences, Inc., a Lubrizol Company, for generic ABRAXANE". Glenmark gets USFDA nod for skin lesion treatment gel
Glenmark Pharmaceuticals has received final approval from the US health regulator for generic Diclofenac Sodium gel used for treatment of skin lesions.Glenmark Pharmaceuticals Inc USA has been grant... Glenmark Pharmaceuticals receives ANDA approval for Diclofenac Sodium Gel, 3%
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated September 14, 2016 titled "Glenmark Pharmaceuticals receives ANDA approval for Diclofenac Sodium Gel, 3%. "
Glenmark gets US nod for generic skin ointment
The Xylocaine ointment has sales of $370 million in the 12 months ended July Glenmark Pharmaceuticals receives ANDA approval for Lidocaine Ointment USP, 5%
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated September 12, 2016 titled 'Glenmark Pharmaceuticals receives ANDA approval for Lidocaine Ointment USP, 5%' Buy Glenmark Pharmaceuticals Ltd., target Rs 940.0 : Kunal Bothra
Buy Glenmark Pharmaceuticals Ltd. at a price target of Rs 940.0 and a stop loss at Rs 886.0 from entry point Buy Glenmark Pharmaceuticals Ltd., target Rs 895.0 : Ashish Kyal
Buy Glenmark Pharmaceuticals Ltd. at a price target of Rs 895.0 and a stop loss at Rs 845.0 from entry point